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Abstract
Background: Venous Thrombo-embolism (VTE – Deep venous thrombosis (DVT) and/or pulmonary embolism (PE) – in
traumatized patients causes significant morbidity and mortality. The current study evaluates the effectiveness of DVT
surveillance in reducing PE, and performs a cost-effectiveness analysis.
Methods: All traumatized patients admitted to the adult ICU underwent twice weekly DVT surveillance by bilateral lower
extremity venous Duplex examination (48-month surveillance period – SP). The rates of DVT and PE were recorded and
compared to the rates observed in the 36-month pre-surveillance period (PSP). All patients in both periods received
mechanical and pharmacologic prophylaxis unless contraindicated. Total costs – diagnostic, therapeutic and surveillance –
for both periods were recorded and the incremental cost for each Quality Adjusted Life Year (QALY) gained was calculated.
Results: 4234 patients were eligible (PSP – 1422 and SP – 2812). Rate of DVT in SP (2.8%) was significantly higher than in PSP
(1.3%) – p,0.05, and rate of PE in SP (0.7%) was significantly lower than that in PSP (1.5%) – p,0.05. Logistic regression
demonstrated that surveillance was an independent predictor of increased DVT detection (OR: 2.53 – CI: 1.462–4.378) and
decreased PE incidence (OR: 0.487 – CI: 0.262–0.904). The incremental cost was $509,091/life saved in the base case,
translating to $29,102/QALY gained. A sensitivity analysis over four of the parameters used in the model indicated that the
incremental cost ranged from $18,661 to $48,821/QALY gained.
Conclusions: Surveillance of traumatized ICU patients increases DVT detection and reduces PE incidence. Costs in terms of
QALY gained compares favorably with other interventions accepted by society.
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Introduction
Venous thrombo-embolism (VTE), encompassing deep vein
thrombosis (DVT) and pulmonary embolism (PE) causes signifi-
cant morbidity and mortality among traumatized patients.
Without prophylaxis, the incidence of DVT is estimated to be
60% [1] dropping to 6–21% with adequate mechanical and/or
pharmacologic prophylaxis. [2–8] In view of this, prophylaxis
against VTE is standard of care for traumatized patients at high
risk of VTE. With or without prophylaxis, patients that do develop
DVT are at risk of short term complications (limb threatening
phlegmasia, and life threatening PE) and long term complications
(post-phlebetic limb, and pulmonary hypertension). Thus the total
burden of VTE in traumatized patients is significant both in terms
of cost and suffering.
Despite adequate prophylaxis, [9] DVT does occur and can be
silent with the first manifestation being a PE that is fatal in 5–10%.
[10,11] Surveillance screening for DVT in high risk patients may
be an effective strategy to diagnose and treat DVT and thus
reduce both short and long term morbidity and mortality. The
current study evaluates the cost effectiveness of such a surveillance
program on traumatized patients at high risk of VTE, with a
particular focus on the quality adjusted life years (QALY) gained
from any reduction in PE.
Materials and Methodology
The study was performed at the level-I trauma center at the
Virginia Commonwealth University (VCU) Medical Center. The
trauma center is a state designated and American College of
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Surgeons verified level-I center in central Virginia serving a
population of two million, with annual trauma admissions of
.4,000. The study was approved by the Institutional Review
Board (IRB) of VCU. The study was exempt from informed
consent since 1. all the data was already gathered in the registry of
the trauma center prior to the conception of the study and 2. data
from the registry was de-identified.
All adult traumatized patients admitted to an intensive care unit
(ICU) were included. During the 36-month pre-surveillance
period, patients received mechanical prophylaxis (thigh-high
sequential compression device) and pharmacologic prophylaxis
[low molecular weight (LMW) heparin], unless contraindicated.
Prophylaxis was initiated within 24 hours of admission. In the year
2000 the institution adopted the policy of initiating un-fractionated
heparin for all head injured patients within 24 hours of admission
unless the patient had an expanding head bleed and this policy was
continued throughout the study period. The prophylaxis protocol
did not change over the time course of the study, and the non-
compliance rate was ,10%. During the 48-month surveillance
period, in addition to pharmacologic prophylaxis, patients
underwent twice weekly DVT surveillance of both lower
extremities by bedside venous Duplex examination, till discharged
from the unit. Surveillance was performed on the lower extremities
since 90% of the PEs originate in the lower extremity, [12] and the
focus of the study was to examine the reduction in PEs by early
detection and prompt therapy of DVT. Patients diagnosed with
clinically significant (popliteal vein or higher) DVT were initially
treated with therapeutic heparin (unfractionated or LMW) and
later either maintained on LMW heparin or changed to oral anti-
coagulation. In instances where therapeutic anti-coagulation was
contra-indicated, or there was progression of VTE despite
adequate anti-coagulation, inferior vena-caval filter was inserted
to prevent PE. Anti-coagulant therapy was continued for at least
six months. DVTs that involved only the infra-popliteal calf veins
were not treated, however prophylaxis and surveillance was
continued.
Each incidence of DVT and PE was recorded. Cost determi-
nations were based on the following: Diagnosis/surveillance for
DVT=$200/duplex study; diagnosis of PE by contrast enhanced
computed tomography (CECT) of chest = $500; VTE therapy
cost = $6,000. [13] During PSP, total cost was calculated by
adding the diagnostic cost of each incidence of DVT (single venous
duplex examination) and PE (single CECT of chest) and the
therapeutic cost of all VTE requiring therapy. For SP surveillance
costs were calculated by multiplying the cost of a single Duplex
study by the average number of studies per ICU patient under
surveillance. The average number of studies per patient was
determined by dividing the average ICU length of stay in days by
3.5 since surveillance studies were performed twice in one week.
To the surveillance cost was added the diagnostic cost of each
incidence of PE, and the therapeutic cost of all VTE requiring
therapy. For cost calculations in SP, it was assumed that all DVT
detected was via surveillance, hence there are no separate
diagnostic cost for DVT.
Statistical and Cost benefit analysis
Uni-variate comparisons were performed using the appropriate
tests – Chi-square, with Fisher’s exact correction where required,
for discrete variables, and Student’s t-test for parametric and
Wilcoxson rank sum test for non-parametric continuous variables.
Regression analysis was performed to evaluate the independent
predictors of DVT and PE including the role of surveillance.
Significance was set at p,0.05. For cost benefit analysis, the total
cost of the program was calculated as detailed above. This cost was
used to calculate the cost per life saved if the program led to a
decrease in number of PEs. All costs were computed in US dollars.
All calculations were performed using Statview software (SAS
Institute Inc Cary NC, USA). All continuous data is presented as
Mean6Standard Error of Mean (SEM).
Results
There were 4234 trauma patients admitted to the ICU during
the 84-month study period (Table 1). The overall characteristics of
the population were similar to most trauma populations with a
relatively young age, and male preponderance. Of these, 1422
were during PSP and 2812 during SP.
VTE
There were 139 incidents of VTE (DVT-96; PE-43) among 129
patients. The characteristics of patients that developed VTE and
those that did not are presented in Table 2. Patients developing
VTE were older with a higher injury severity score (ISS) – p,0.05
for both. VTE was more common in males, and those that suffered
blunt trauma, though these differences were not statistically
significant – p.0.05 for both. VTE was also more common in
patients sustaining injuries to face, chest and extremity as
evidenced by the higher abbreviated injury scale (AIS) for these
body regions – p,0.05 for all. Older age and higher ISS was
observed in the DVT patients (p,0.05), but only ISS was
significantly higher in the PE patients (p,0.05). Like VTE in
general, both DVT and PE patients demonstrated a male
preponderance and more blunt mechanism, however these
differences were not statistically significant (p.0.05). Among the
96 DVTs, 18 were in PSP, and of these nine (50%) were clinically
significant, requiring therapy as per protocol. The remaining 78
DVTs were in SP, and of these 47 (60%) were clinically significant.
Five of these 47 were in patients in whom surveillance had
previously detected calf vein DVT, and with continued surveil-
lance the DVT was observed to progress. Of the 43 PEs, 22 were
in PSP and 21 in SP.
The rate of DVT increased while the rate of PE decreased
between PSP and SP. The overall rate of DVT was 2.2% (96/
4234). The rate during PSP was 1.3% (18/1422), and with
surveillance, the rate increased by 115% to 2.8% (78/2812). The
overall rate of PE was 1% (43/4234). The rate of PE during SP
(0.7% – 21/2812) was 50% lower than in PSP (1.5% – 22/1422).
The differences in the rates of both DVT and PE during PSP vs
SP, were statistically significant – p,0.05 for both (Fig. 1). Since
there were some differences in the patient population and injury
characteristics between the two periods (Table 1), a logistic
regression model was constructed to identify independent predic-
tors of DVT and PE (Table 3). Among the patient and injury
characteristics, age, ISS and AIS of extremity were independently
predictive of DVT, and AIS of chest and extremity were
independently predictive of PE. After controlling for all variables
identified, surveillance was an independent predictor of increased
DVT detection (OR 2.53 with 95% CI of 1.462–4.378) and of
decreased PE incidence (OR 0.487 with 95% CI of 0.262–0.904).
Outcomes
Occurrence of VTE significantly worsened outcomes in terms of
increased mortality and longer lengths of stay in the ICU and the
hospital – p,0.05 for all (Table 2). These differences remained
when the VTE group was separated into those with DVT and
those with PE (Table 2). Overall mortality in PSP was 9.1% and in
SP was 8.9% (p.0.05).
DVT Surveillance in ICU
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Data assumptions, and Cost calculations
To compute the incremental cost/QALY gained, the following
assumptions were made:
1. Attention was restricted to men aged 50 and older to be
consistent with the cohort studied. Survival for men up to age
99 was computed using CDC data. [14]
2. The base case health utility for all patients was 0.9, which is
consistent with publicly reported values associated with DVT.
[15] For sensitivity analysis, this was varied from 0.8–1.0.
3. All health effects were discounted at 3% which is also standard
in terms of reduction in quality of life with age. For sensitivity
analysis the discount rate was varied from 0–5%.
4. To calculate cost per life saved, it was assumed that the main
difference between SP and PSP was a reduction in PEs. The
difference in PE incidence rate between PSP and SP was
computed using the observations from the study – an absolute
reduction of 0.8% (1.5% in PSP to 0.7% in SP). For sensitivity
analysis 95% confidence interval for the reduction in the PE
rate was utilized. This, using the normal approximation to the
binomial distribution, is 0.2%–1.4%.
Table 1. Patient populations in the two periods of study.
PSP (n=1422) SP (n =2812)
Age (years) 40.7660.50 40.6960.36
Gender (% male:female) 72:28 73:27
Mechanism (% blunt:penetrating)* 81:19 84:16
ISS* 19.3760.33 20.8960.25
RTS 6.9560.05 6.8960.04
AIS
Head* 2.9360.04 3.1460.03
Face* 1.4260.03 1.9560.03
Chest* 3.0560.04 3.2960.02
Abdomen 2.7460.04 2.6660.03
Extremity* 2.2860.03 2.5560.02
External* 1.1260.04 1.0460.01
Inferior Vena Caval filter* 34 (2%) 28 (1%)
Mortality 129 (9.1%) 250 (8.9%)
*p,0.05: PSP vs SP. PSP: pre-surveillance period, SP: surveillance period, ISS: injury severity score, RTS: revised trauma score, AIS: Abbreviated Injury Scale.
doi:10.1371/journal.pone.0106793.t001
Table 2. Details and outcomes of patients developing venous thrombo-embolism (VTE) or not.
No VTE (n=4105) VTE (n =129) DVT (n =96) PE (n =43)
Age (years)*# 40.5260.3 47.1161.62 48.5161.99 42.9062.30
Gender (% male:female) 72:28 78:22 78:22 84:16
Mechanism (%blunt:penetrating) 83:17 87:13 85:15 93:7
ISS*#‘ 20.0960.20 28.4661.13 29.6760.20 25.6661.81
RTS 6.9160.03 6.7260.18 6.8260.19 6.5460.42
AIS
Head 3.0760.02 3.2260.13 3.0760.02 3.2360.26
Face* 1.7060.02 1.9260.12 1.8660.14 2.0060.22
Chest*# 3.2160.02 3.4460.10 3.6060.11 3.1960.19
Abdomen 2.6960.02 2.7860.12 2.7960.13 2.7660.25
Extremity*# 2.4460.02 2.6460.08 2.7060.08 2.5060.14
External 1.0460.01 1.0660.06 1.0860.08 1.0060.00
ICULOS (days)*#‘ 5.5960.14 20.1561.67 22.0362.02 13.1962.12
HLOS (days)*#‘ 11.7860.23 35.8862.76 36.9063.09 30.7964.87
Mortality*#‘ 356 (8.3%) 23 (17.8%) 16 (16.7%) 8 (18.6%)
Among those developing VTE, details of those developing deep vein thrombosis (DVT), or pulmonary embolism (PE). p,0.05: *No VTE vs VTE, #No DVT vs DVT, ‘No PE
vs PE. ISS: injury severity score, RTS: revised trauma score, AIS: abbreviated injury scale, ICULOS: Intensive Care Unit Length of Stay, HLOS: Hospital Length of Stay.
doi:10.1371/journal.pone.0106793.t002
DVT Surveillance in ICU
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5. The PE fatality rate for the base case was assumed to be 7.5%,
and a range from 5–10% was considered for sensitivity analysis.
[10,11]
6. Those who survive PE suffer from a short-term loss in 0.0115
QALYs due to short-term hospitalization. [16]
The total VTE related patient care cost during PSP (diagnostic
and therapeutic) was $194,600/1422 patients – $136,850/1000
patients and during SP (diagnostic, therapeutic and surveillance)
was $1,244,100/2812 patients – $442,425/1000 patients. Thus,
the total additional cost of the surveillance program was
$305,575/1000 patients. During this period the PE rate decreased
from 1.5% to 0.7% or, eight PEs were prevented per 1000 patients
placed under surveillance. Assuming a base case PE fatality rate of
7.5%, it is necessary to prevent 13.33 PEs in order to save one life.
This translates to 1666 patients placed under surveillance at a cost
of $509,091 per life saved.
The incremental cost per QALY saved was computed as
follows. Future expected life years were computed using CDC
mortality data for men aged 50 and over to be consistent with the
cohort studied. [14] Given these assumptions, patients not
experiencing a PE fatality would live an additional 30.31 expected
life years, which translates to an additional 17.49 quality-adjusted/
discounted life years with a health state utility of 0.9. This yielded
an incremental cost of $29,102/QALY gained for the base case.
Discussion
VTE is a major problem for high risk trauma patients. A large
body of literature has established that trauma patients are at
higher risk of developing DVT that can lead to mortality from PE,
and both short and long term morbidity. Without prophylaxis the
incidence of DVT in trauma patients has been reported to be as
high as 60%. [1] This has resulted in some form of prophylaxis
becoming a standard of care for all high risk trauma patients. [17]
Despite prophylaxis, DVT occurs in 6–12% of trauma patients.
[8] Oftentimes the DVT itself is silent, with the first sign of VTE
being a pulmonary embolism that is fatal in 5–10% of instances.
[10,11] Routine surveillance for DVT maybe a method to
diagnose DVT at an asymptomatic stage, with the hope that by
therapy and/or placement of a protective inferior vena-caval filter,
a large hemodynamically compromising or fatal PE will be
prevented. The value and cost-effectiveness of this approach is
debated. In an early prospective study, Piotrowski et al reported on
343 high-risk trauma patients placed on DVT surveillance and
concluded that since with prophylaxis the risk of DVT was low,
the cost of detecting a single DVT by surveillance was extremely
high. [18] They did however suggest that routine DVT
surveillance may reduce the risk of PE. [18] In a retrospective
study Meyer et al reported on traumatized ICU patients and
concluded that at US$ 6688/DVT detected, the cost was too high
to recommend routine surveillance, but it should be considered in
patients at the highest risk. [19] Major et al reported on 726
patients admitted to the surgical ICU (majority due to trauma) of
which some underwent routine DVT surveillance and concluded
that with adequate prophylaxis the incidence of both DVT and PE
were low and hence, surveillance was not indicated. [20] Similar
doubts regarding the utility and cost-effectiveness of surveillance
have been reported by others. [21–24] Based on the results of
these studies, the latest edition (9th) of the American College of
Chest Physicians (ACCP) evidenced based guidelines on DVT
prevention state that the benefit of DVT surveillance by duplex
sonography in reducing the incidence of PE and mortality is
unclear. Additionally, since up to 30% of screen positives maybe
false, [25] there is potential harm in that the falsely positive
patients may get unnecessary anticoagulation therapy with its
attendant risks. [9] On the other hand, Napolitano et al reported
on 458 high-risk traumatized patients that underwent routine
surveillance, and found a significant incidence of asymptomatic
DVT concluding that for the high-risk trauma patient, surveillance
is justified. [26] Adams et al, in a large recent study involving.
4,000 traumatized patients of whom 982 high-risk patients were
placed on DVT surveillance, reported that 86% of the lower
extremity DVTs were clinically silent and detected by surveillance.
They concluded that surveillance was justified in this patient
population. [27] In light of these conflicting conclusions, the CDC
convened a panel of experts to examine and advise about the
utility of DVT surveillance in hospitalized patients. The panel
recommended that surveillance can provide robust data on the
Figure 1. Figure showing the rates of deep vein thrombosis
(DVT) and pulmonary embolism (PE) during the pre-surveil-
lance period (PSP: 2001–03) and the surveillance period (SP:
2004–07). #p,0.05 – DVT (PSP vs SP); *p,0.05 – PE (PSP vs SP).
doi:10.1371/journal.pone.0106793.g001
Table 3. Results of logistic regression showing the independent predictors of Deep Vein Thrombosis (DVT) and Pulmonary
Embolism (PE).
DVT PE
OR 95% CI OR 95%CI
Age 1.022 1.011–1.032 - -
ISS 1.039 1.023–1.055 - -
AIS Chest - - 1.318 1.094–1.587
AIS Extremity 1.379 1.168–1.627 1.297 1.025–1.641
OR: odds ratio, CI: confidence interval, ISS: injury severity score, AIS: abbreviated injury scale.
doi:10.1371/journal.pone.0106793.t003
DVT Surveillance in ICU
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epidemiology of VTE and effectiveness of prevention programs
however more data was needed regarding the utility of surveillance
itself in improving patient outcomes. [28] The current study
reports on a surveillance program at a busy level-I trauma center,
and aims at performing a detailed cost effectiveness analysis of
such a program. In the current economic and healthcare
environment, merely demonstrating a medical benefit may no
longer be enough to support an intervention. The direct cost and
the resultant benefit has to be at a level that society is willing and
able to afford. Past DVT surveillance studies have focused on
establishing the incidence and risk factors for VTE, however, to
the best of our knowledge, this is the first report of QALY based
cost effectiveness analysis of such a program in an acute care
setting.
VTE was seen more often in older patients with a higher ISS
and those with injuries to extremity and the chest regions. This is
similar to what has been reported in many studies. [1,6,7,18,27]
Unlike other studies, the current study failed to demonstrate a
higher incidence of VTE in head injured patients. This may be
related to the very aggressive prophylaxis program instituted at
our institution in 2000 where all head injured patients received
unfractionated heparin within 24 hours of admission, unless the
repeat CT demonstrated expansion of intra-cranial hemorrhage.
Surveillance resulted in higher numbers of DVTs being diagnosed
Figure 2. Figure showing a sensitivity analysis on the incremental cost to obtain one additional QALY. The bars represent upper and
lower bounds on the incremental cost relative to the base case of $29,102 (dashed line) with respect to the bounds on each parameter value. In this
figure, the discount rate ranges from 0% to 5%, the difference in the PE incidence rate between PSP and SP ranges from 0.2% to 1.4%, the PE fatality
rate ranges from 5% to 10%, and the health state utility ranges from 0.8 to 1.0.
doi:10.1371/journal.pone.0106793.g002
Figure 3. Incremental dollar cost per quality adjusted life year (QALY) saved for selected interventions as compared to the cost of
deep venous thrombosis surveillance (DVT Sur.). The bars represent range of cost from the best case scenario (most cost effective) to the
worst case scenario (least cost effective) for each intervention. CPR: cardio-pulmonary resuscitation, APC: activated protein C for sepsis, tPA for AMI:
tissue plasminogen activator for acute myocardial infarction, CABG: coronary artery bypass grafting, NICU: neonatal intensive care unit. The bracketed
number represents the reference the data is derived from.
doi:10.1371/journal.pone.0106793.g003
DVT Surveillance in ICU
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and treated, and at the same time, lowering the incidence of PE
(Fig. 1). Regression analysis demonstrated surveillance to be an
independent predictor of increased DVT detection and decreased
PE incidence. We believe that the increase in the numbers of DVT
diagnosed, and treated directly resulted in a lower incidence of PE.
While clearly effective in decreasing the number of PEs, we did not
see a significant decrease in mortality. The total incidence of PE
was 43 or 1% of the total population. This coupled with the known
PE fatality rate of 5–10% means that a very large number of
patients will be required to demonstrate a significant decrease in
the PE related mortality by such a surveillance program.
In the current study, the incremental cost per life saved was
$509,091. In comparison, post-exposure prophylaxis against rabies
is estimated to cost.$500,000 per life saved. [29] In the non-
disease arena, in 2002, The National Highway Traffic Safety
Administration (NHTSA) evaluated the cost benefit of all
mandated Federal Motor Vehicle Safety Standards (FMVSS).
The report concluded that these standards helped save 20,851
lives in 2002 at a cost of $544,482 per life saved. [30] There was
only one study that directly evaluated cost-effectiveness of DVT
surveillance. In that 1996 study on traumatic and non-traumatic
brain injured patients, that underwent a single screening duplex
examination at the time of admission to the rehabilitation unit, the
cost per life saved was $129, 527. [31] The cost in the current
study is much higher. The reasons for that are likely twofold: first
is medical care cost inflation, with the current study basing all costs
of 2004 estimates as compared to the cited study on 1996
estimates, and secondly, the current study bases costs on twice
weekly surveillance examinations, while the brain injury study had
a single screening examination at the time of admission only. Cost
per life saved however, is a very crude measure of cost benefit
evaluation since the method treats each life saved as equivalent
irrespective of the future life expectancy at the age death was
prevented.
In the current study, to account for the difference in the
quantity and quality of life saved, the incremental cost per QALY
was computed at $29,102/QALY gained. To further analyze this
value, a uni-variate sensitivity analysis was performed over four of
the parameters used in the cost-effectiveness analysis: the discount
rate (base case 3% with range of 0%–5%), the difference in the PE
incidence rate between PSP and SP (base case 0.8% with range of
0.2%–1.4%), the PE fatality rate (base case 7.5% with range of
5%–10%), and the health state utility (base case 0.9 with range of
0.8–1.0). The resulting incremental costs per QALY saved in the
uni-variate sensitivity analysis are illustrated in Fig. 2. The results
show that the incremental costs are relatively insensitive to the
health state utility ($26,191 – $32,739). The results are somewhat
more sensitive to the PE fatality rate, the reduction in the PE rate,
and the discount rate, which result in incremental costs per QALY
saved of $21,829 – $43,652, $20,729 – $48,821, and $18,661 –
$36,905, respectively. The sensitivity analysis results suggests that
in all scenarios, the incremental costs compares well with a
number of other life saving interventions that are accepted by
society in the medical and non-medical arenas as shown in Fig. 3
(compiled from references [32–41].
The question as to how much a society is able and willing to
afford for each QALY saved is a difficult one. The answer depends
upon the societal values and the economic status of an individual
society. In the United States a figure of $50,000 per QALY saved
is oftentimes utilized to make decisions about resource allocation.
[42] Recently that figure has been questioned and it is argued that
based on current societal expectations, the figure should be
significantly higher. [30] However, even by the traditional model
of $50,000 per QALY saved as cost effective, the DVT
surveillance program is cost effective under nearly all of the
scenarios considered.
There are some limitations to this study. Firstly, it is a
retrospective analysis. Due to this, we cannot be sure of the
compliance with surveillance. Second, it is not powered to
demonstrate a difference in mortality. Since with prophylaxis,
the incidence of PE is low (,1%) and the mortality from PE is ,
10%, only a very large multi-institutional study could have enough
power to demonstrate a difference in PE related mortality. Third,
even though the prophylaxis protocol has not changed over the
study period, some other subtle changes may have occurred that
are missed in a study spanning seven years. Finally, probably the
most significant limitation of the study is that while the increased
DVT detection and decreased PE incidence were directly
observed (measured) and are likely due to surveillance, all the
cost calculations leading to the dollar cost/QALY gained, are
extrapolations of the data and represent potential estimates per
QALY gained, if the observations of this study true. As mentioned
above, the study is not large enough to demonstrate an actual
difference in mortality that maybe attributable to surveillance.
Despite these limitations, the study demonstrates that DVT
surveillance among traumatized ICU patients increases DVT
detection, decreases PE incidence and is cost-effective.
Conclusions
A DVT surveillance program for trauma patients admitted to
the ICU at high risk for VTE, is effective in reducing the incidence
of PE, and cost effective in terms of preventing fatal PE.
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